Characterization of Enterococcus Faecalis Endocarditis and Impact of Amoxicillin MIC Elevation on Patient Outcome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05530837

Acronym

ENDO_ENTERO

Enrollment

281

Registered

2022-09-07

Start date

2022-06-08

Completion date

2023-03-15

Last updated

2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Endocarditis

Brief summary

Infective endocarditis is a complex infection that can be life-threatening. These infections also cause anatomical lesions that can be severe. Their management is complex and involves several disciplines: cardiology, bacteriologists, infectious diseases specialists, radiologists, nuclear medicine specialists, cardiac surgeons, neurologists, pharmacologists, etc. The incidence of Enterococcus faecalis endocarditis is increasing due to the aging of the population and the disappearance of rheumatic fever. The adequate management of these infections is complex and relies on the prolonged administration of high-dose antibiotics, classically the combination of amoxicillin and ceftriaxone. In the context of Streptococcal endocarditis, the impact of increasing the Minimum Inhibitory Concentration (MIC) of amoxicillin on patient mortality has been demonstrated but no study has yet examined the impact of increasing the MIC of amoxicillin on the outcome of patients treated for Enterococcus faecalis infective endocarditis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient over 18 years of age with a diagnosis of Enterococcus faecalis infective endocarditis based on Duke criteria * Patient hospitalized in one of the participating centers * French-speaking patient

Exclusion criteria

* Patient with suspected infective endocarditis who does not meet Duke criteria * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under court protection * Patient objecting to the use of their data for this research

Design outcomes

Primary

Measure	Time frame	Description
Describe the epidemiology and clinical presentations of patients with Enterococcus faecalis endocarditis	Month 1	This outcome corresponds to the evaluation of factors associated with mortality in patients with Enterococcus faecalis endocarditis.

Secondary

Measure	Time frame	Description
Impact of increasing the minimum inhibitory concentrations of amoxicillin on the outcome of Enterococcus faecalis infective endocarditis	Month 1	This outcome corresponds to the description of the epidemiology of Enterococcus faecalis endocarditis in France.

Countries

France

Outcome results